AC Immune begins phase 1 trial of brain-penetrant inflammation drug
Tweet Send to a Friend
AC Immune SA (NASDAQ: ACIU) announced it has dosed the first participant in a Phase 1 clinical trial of ACI-19764 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
